Aeterna Zentaris Inc logo

AEZS - Aeterna Zentaris Inc Share Price

$0.489 -0.0  -3.1%

Last Trade - 3:55pm

Sector
Healthcare
Size
Micro Cap
Market Cap £24.3m
Enterprise Value £19.3m
Revenue £1.12m
Position in Universe 5080th / 6403
Bullish
Bearish
Unlock AEZS Revenue
Momentum
Relative Strength (%)
1m +18.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -80.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.011 0.55 0.91 0.92 26.9 0.53 41.5 11.9 +117.2%
-91.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AEterna Zentaris Inc. revenues increased from $231K to $1.2M. Net loss decreased 43% to $2.7M. Revenues reflect Product sales increase from $129K to $1M, Supply chain increase of 80% to $81K, Royalty income increase of 14% to $24K. Lower net loss reflects General and administrative expenses decrease of 36% to $2.3M (expense), Restructuring costs decrease from $773K (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AEZS Revenue Unlock AEZS Revenue

Net Income

AEZS Net Income Unlock AEZS Revenue

Normalised EPS

AEZS Normalised EPS Unlock AEZS Revenue

PE Ratio Range

AEZS PE Ratio Range Unlock AEZS Revenue

Dividend Yield Range

AEZS Dividend Yield Range Unlock AEZS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AEZS EPS Forecasts Unlock AEZS Revenue
Profile Summary

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 12, 1990
Public Since December 19, 1995
No. of Shareholders: n/a
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 62,678,613
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AEZS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AEZS
Upcoming Events for AEZS
Frequently Asked Questions for Aeterna Zentaris Inc
What is the Aeterna Zentaris Inc share price?

As of 3:55pm, shares in Aeterna Zentaris Inc are trading at $0.489, giving the company a market capitalisation of £24.3m. This share price information is delayed by 15 minutes.

How has the Aeterna Zentaris Inc share price performed this year?

Shares in Aeterna Zentaris Inc are currently trading at $0.489 and the price has moved by -79.75% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aeterna Zentaris Inc price has moved by -82.74% over the past year.

What are the analyst and broker recommendations for Aeterna Zentaris Inc?

Of the analysts with advisory recommendations for Aeterna Zentaris Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Aeterna Zentaris Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Aeterna Zentaris Inc next release its financial results?

Aeterna Zentaris Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Aeterna Zentaris Inc dividend yield?

Aeterna Zentaris Inc does not currently pay a dividend.

Does Aeterna Zentaris Inc pay a dividend?

Aeterna Zentaris Inc does not currently pay a dividend.

When does Aeterna Zentaris Inc next pay dividends?

Aeterna Zentaris Inc does not currently pay a dividend.

How do I buy Aeterna Zentaris Inc shares?

To buy shares in Aeterna Zentaris Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aeterna Zentaris Inc?

Shares in Aeterna Zentaris Inc are currently trading at $0.489, giving the company a market capitalisation of £24.3m.

Where are Aeterna Zentaris Inc shares listed? Where are Aeterna Zentaris Inc shares listed?

Here are the trading details for Aeterna Zentaris Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: AEZS
What kind of share is Aeterna Zentaris Inc?

Based on an overall assessment of its quality, value and momentum, Aeterna Zentaris Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aeterna Zentaris Inc share price forecast 2020?

We were not able to load any forecast data for Aeterna Zentaris Inc.

How can I tell whether the Aeterna Zentaris Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aeterna Zentaris Inc. Over the past six months, the relative strength of its shares against the market has been -56.79%. At the current price of $0.489, shares in Aeterna Zentaris Inc are trading at -40.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aeterna Zentaris Inc PE Ratio?

We were not able to find PE ratio data for Aeterna Zentaris Inc.

Who are the key directors of Aeterna Zentaris Inc?

Aeterna Zentaris Inc's management team is headed by:

M. Marcel Aubut - IND
Gilles Gagnon - DRC
Eckhard Gunther - VPR
Gerard Limoges - IND
Juergen Ernst - IND
Jose Dorais - IND
Carolyn Egbert - CHM
David Dodd - DRC
Jude Dinges - SVP
Richard Sachse - SVP
Philip Theodore - SEC
Michael Teifel - VPR
Michael Ward - PRE
John Sharkey - OTH
Leslie Auld - CFO
Klaus Paulini - PRE
Who are the major shareholders of Aeterna Zentaris Inc?

Here are the top five shareholders of Aeterna Zentaris Inc based on the size of their shareholding:

Lind Global Macro Fund LP Corporation
Percentage owned: 6.2% (3.89m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 1.94% (1.21m shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 1.28% (802k shares)
Ikarian Capital LLC Hedge Fund
Percentage owned: 0.19% (117k shares)
J.P. Morgan Securities LLC Research Firm
Percentage owned: 0.15% (91.8k shares)
Similar to AEZS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.